Aug. 8 at 10:00 PM
$CALC
The single biggest potential catalyst, in my view, would be a concrete timeline for the pancreatitis pivotal program. If management gives something like “we expect to initiate in Q4 2026 and anticipate topline data in H2 2027”, that would be considerably more meaningful than generic statements about progressing Auxora.
If what you meant was the actual English transcript/summary of the forthcoming earnings call, I can also prepare a “bullish / neutral / bearish” interpretation guide, with the exact phrases to listen for and what each would imply for the share price.
